SI2086332T1 - Iz kostnega mozga pridobljene mezenhimske matične celice kot vir nevralnih predhodnikov - Google Patents

Iz kostnega mozga pridobljene mezenhimske matične celice kot vir nevralnih predhodnikov Download PDF

Info

Publication number
SI2086332T1
SI2086332T1 SI200732020T SI200732020T SI2086332T1 SI 2086332 T1 SI2086332 T1 SI 2086332T1 SI 200732020 T SI200732020 T SI 200732020T SI 200732020 T SI200732020 T SI 200732020T SI 2086332 T1 SI2086332 T1 SI 2086332T1
Authority
SI
Slovenia
Prior art keywords
stem cells
mesenchymal stem
neural
bone marrow
neural precursors
Prior art date
Application number
SI200732020T
Other languages
English (en)
Inventor
Saud A. Sadiq
Violane K. HARRIS
Original Assignee
Multiple Sclerosis Research Center Of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Multiple Sclerosis Research Center Of New York filed Critical Multiple Sclerosis Research Center Of New York
Publication of SI2086332T1 publication Critical patent/SI2086332T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1353—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from bone marrow mesenchymal stem cells (BM-MSC)

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Claims (9)

  1. Iz kostnega mozga pridobljene mezenhimske matične celice kot vir nevralnih predhodnikov Patentni zahtevki
    1. Postopek za in vitro diferenciacijo nevralnih prekurzorskih celic iz mezenhimskih matičnih celic, pridobljenih iz kostnega mozga, pri čemer postopek obsega: (a) ekspandiranje izoliranih iz kostnega mozga pridobljenih mezenhimskih matičnih celic, pobranih od pacienta, v bazalnem mediju, ki obsega avtologni rastni serum, pridobljen od pacienta; (b) gojenje in izoliranje iz mezenhimskih matičnih celic pridobljenih nevralnih prekurzorskih celic od mezenhimskih matičnih celic; in (c) izvajanje analize izražanja genov za identificiranje iz mezenhimskih matičnih celic pridobljenih nevralnih predhodnikov, ki kažejo 2-4-kratno povečanje količine nestina, 5-15-kratno povečanje količine nevrofilamenta, 7-10-kratno povečanje količine GFAF (glialna fibrilarna kisla beljakovina) in 0,4-0,7-kratno zmanjšanje vimentina.
  2. 2. Postopek po zahtevku 1, pri čemer korak (b) obsega gojenje mezenhimskih matičnih celic, pridobljenih iz koraka (a) v bazalnem mediju nevralnih prednikov (NPBM), obogatenem z nevronskim preživetvenim faktorjem-1 (NSF-1), 20 ng/ml epidermalnega rastnega faktorja (EGF) in 20 ng/ml bazičnega fibroblastnega rastnega faktorja (bFGF), da nastanejo nevralni predniki.
  3. 3. Postopek po zahtevku 2, pri čemer je EGF rekombinantni človeški EGF (rhEGF) in bFGF je rekombinantni človeški bFGF (rhbFGF).
  4. 4. Postopek po katerem koli predhodnem zahtevku, pri čemer se mezenhimske matične celice v koraku (a) in nevralni prekurzorji v koraku (b) gojijo na gojitvenih bučkah 2 majhnim sprijemanjem.
  5. 5. Postopek po katerem koli od zahtevkov od 2 do 4, pri čemer se nevralni prekurzorji izolirajo tako, da se poberejo plavajoče celične gruče nevralnih prekurzorjev, prednostno s centrifugiranjem, in se pobrane celice resuspendirajo v oplemenitenem gojitvenem mediju NPBM.
  6. 6. Postopek po zahtevku 5, pri čemer se pobiranje plavajočih celičnih gruč nevralnih prekurzorjev in resuspendiranje v oplemenitenem gojitvenem mediju NPBM opravi vsakih 2-3 dni.
  7. 7. Postopek po katerem koli predhodnem zahtevku, pri čemer se iz matičnih celic pridobljeni nevralni prekurzorji gojijo v koraku (b) 10-15 dni.
  8. 8. Postopek po katerem koli predhodnem zahtevku, pri čemer analiza izražanja genov obsega analiziranje RNA-ravni nestina, nevrofilamenta, glialne fibrilarne kisle beljakovine (GFAP) in vimentina v vzorcu nevronskih prekurzorskih celic in vzorcu mezenhimskih matičnih celic.
  9. 9. Postopek po katerem koli predhodnem zahtevku, pri čemer ima posameznik multiplo sklerozo.
SI200732020T 2006-11-03 2007-11-02 Iz kostnega mozga pridobljene mezenhimske matične celice kot vir nevralnih predhodnikov SI2086332T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85651506P 2006-11-03 2006-11-03
EP07867349.8A EP2086332B1 (en) 2006-11-03 2007-11-02 Bone marrow-derived mesenchymal stem cells as a source of neural progenitors
PCT/US2007/023184 WO2008057443A2 (en) 2006-11-03 2007-11-02 Bone marrow-derived mesenchymal stem cells as a source of neural progenitors

Publications (1)

Publication Number Publication Date
SI2086332T1 true SI2086332T1 (sl) 2018-06-29

Family

ID=39365076

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200732020T SI2086332T1 (sl) 2006-11-03 2007-11-02 Iz kostnega mozga pridobljene mezenhimske matične celice kot vir nevralnih predhodnikov

Country Status (15)

Country Link
US (5) US8642331B2 (sl)
EP (2) EP2086332B1 (sl)
CA (1) CA2668200C (sl)
CY (1) CY1120115T1 (sl)
DK (1) DK2086332T3 (sl)
ES (1) ES2663875T3 (sl)
HR (1) HRP20180533T1 (sl)
HU (1) HUE036745T2 (sl)
LT (1) LT2086332T (sl)
MX (1) MX2009004776A (sl)
PL (1) PL2086332T3 (sl)
PT (1) PT2086332T (sl)
RS (1) RS57083B1 (sl)
SI (1) SI2086332T1 (sl)
WO (1) WO2008057443A2 (sl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2086332B1 (en) 2006-11-03 2018-01-10 Multiple Sclerosis Research Center Of New York Bone marrow-derived mesenchymal stem cells as a source of neural progenitors
US9301975B2 (en) 2009-05-01 2016-04-05 Biocardia, Inc. Method of preparing autologous cells and method of use for therapy
US20120020931A1 (en) 2010-06-02 2012-01-26 Rutgers, The State University Of New Jersey Therapeutic encapsulated embryonic stem cells and mesenchymal stromal cells
ES2738115T3 (es) 2010-08-18 2020-01-20 Theresa Deisher Dexametasona para su uso en el tratamiento de osteoartritis, fallo hepático, diabetes mellitus tipo-2, ictus y enfermedad de Parkinson, en combinación con un tratamiento con células madre
EP3679939A1 (en) 2010-10-08 2020-07-15 Mesoblast International Sàrl Enhanced msc preparations
WO2012070964A1 (ru) * 2010-11-22 2012-05-31 Farber Boris Slavinovich Модифицированные олигопептиды с противораковыми свойствами и способ их получения
AU2014335680A1 (en) * 2013-10-14 2016-04-07 Hadasit Medical Research Services & Development Limited Method of obtaining terminally differentiated neuronal lineages and uses thereof
WO2015143074A1 (en) * 2014-03-20 2015-09-24 University Of Southern California Brain cancer immunotherapy
WO2016168993A1 (en) 2015-04-22 2016-10-27 Innolife Co., Ltd. Methods of tissue repair and regeneration
EP3307072A4 (en) 2015-06-15 2019-04-03 Mayo Foundation for Medical Education and Research USE OF AUTOLOGOUS MESENCHYMAL STEM CELLS FOR THE TREATMENT OF MULTISYSTEM ATROPHY
US20180369287A1 (en) 2015-10-08 2018-12-27 Neurona Therapeutics Inc. Neural precursor cell populations and uses thereof
CN110709091A (zh) 2017-05-15 2020-01-17 干细胞医药有限公司 使用长效格拉替雷和脂肪源性干细胞治疗多发性硬化症
US11510946B2 (en) 2017-05-15 2022-11-29 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with adipose-derived stem cells
WO2021020666A1 (en) * 2019-07-26 2021-02-04 Brexogen Inc. Precursor cells of induced pluripotent stem cell-derived mesenchymal stem cells and method for preparing the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037719B1 (en) * 1999-02-12 2006-05-02 Stemcells California, Inc. Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
US8017112B2 (en) * 1999-05-14 2011-09-13 Henry Ford Health System Transplantation of bone marrow stromal cells for treatment of neurodegenerative diseases
US20040208858A1 (en) * 2000-04-12 2004-10-21 Gihan Tennekoon Therapeutic uses for mesenchymal stromal cells
EP1452586B1 (en) * 2001-10-30 2012-05-30 Nc Medical Research Inc. Method of inducing differentiation of mesodermal stem cells into nervous system cells
ES2524996T3 (es) * 2005-06-16 2014-12-16 Ramot At Tel Aviv University Ltd. Células aisladas y poblaciones que comprenden a las mismas para el tratamiento de enfermedades del SNC
EP2086332B1 (en) 2006-11-03 2018-01-10 Multiple Sclerosis Research Center Of New York Bone marrow-derived mesenchymal stem cells as a source of neural progenitors

Also Published As

Publication number Publication date
US20150064145A1 (en) 2015-03-05
EP3031326A3 (en) 2016-09-14
US20100166712A1 (en) 2010-07-01
ES2663875T3 (es) 2018-04-17
US9328329B2 (en) 2016-05-03
EP2086332A4 (en) 2010-08-11
CA2668200A1 (en) 2008-05-15
DK2086332T3 (en) 2018-04-16
PL2086332T3 (pl) 2018-07-31
US20150118198A1 (en) 2015-04-30
PT2086332T (pt) 2018-04-04
WO2008057443A9 (en) 2008-07-17
EP2086332A2 (en) 2009-08-12
CY1120115T1 (el) 2018-12-12
LT2086332T (lt) 2018-04-25
CA2668200C (en) 2017-04-18
US20110236357A1 (en) 2011-09-29
US9657268B2 (en) 2017-05-23
EP2086332B1 (en) 2018-01-10
US20140308745A1 (en) 2014-10-16
RS57083B1 (sr) 2018-06-29
HUE036745T2 (hu) 2018-07-30
EP3031326A2 (en) 2016-06-15
MX2009004776A (es) 2009-07-14
WO2008057443A3 (en) 2008-11-20
US8642331B2 (en) 2014-02-04
WO2008057443A2 (en) 2008-05-15
HRP20180533T1 (hr) 2018-05-18

Similar Documents

Publication Publication Date Title
SI2086332T1 (sl) Iz kostnega mozga pridobljene mezenhimske matične celice kot vir nevralnih predhodnikov
CN103031275A (zh) 脐带间充质干细胞分化为神经干细胞的诱导方法
CN112048470B (zh) 一种利用人诱导多能干细胞制备临床级别间充质干细胞制剂的方法
CN104774808B (zh) 将脐带间充质干细胞诱导分化成γ-氨基丁酸能神经元的方法
CN113151149A (zh) 一种经济简便诱导肺类器官的方法及实验模型的建立
Dai et al. The Human Skin‐Derived Precursors for Regenerative Medicine: Current State, Challenges, and Perspectives
KR20190060716A (ko) 무혈청 배지 조성물
CN108998410A (zh) 蛋白激酶抑制剂在抑制单倍体细胞二倍化中的用途
CN104789531B (zh) 一种将脐带间充质干细胞诱导分化成多巴胺能神经元的方法
US20200199531A1 (en) 3d suspension method for generating autologous melanocyte by inducing ips cells and application thereof
JPWO2006028049A1 (ja) アストロサイト様細胞馴化培地の製造方法
CN112852709A (zh) 小鼠肺类器官培养方法
KR101760239B1 (ko) 세포배양 삽입체를 이용한 인간 배아줄기세포 유래 중간엽 세포의 분리방법
Goorha et al. Culturing and neuronal differentiation of human dental pulp stem cells
CN107164325B (zh) MSCs来源的少突胶质细胞的制备方法及试剂盒
KR101204894B1 (ko) 줄기세포의 외배엽성 세포로의 분화 방법
EP1775340A1 (en) Method of cell transdifferentiation
Yasuda et al. Development of cystic embryoid bodies with visceral yolk-sac-like structures from mouse embryonic stem cells using low-adherence 96-well plate
CN100475956C (zh) 制备用于移植的细胞的方法
CN106085951A (zh) 一种建立可持续传代的树鼩精原干细胞细胞系的方法
CN111235110A (zh) 一种神经干细胞的体外培养方法
EP3875581A1 (en) Automated method for preparing keratinocytes
US20230119089A1 (en) Method for differentiating pluripotent stem cells into underlying connective tissue fibroblasts of an epithelium
CN118048296B (zh) 一种用于细胞重编程的培养体系、试剂盒及方法
CN106754652B (zh) iPS细胞分化成外胚层祖细胞的无血清诱导培养基及诱导方法